Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Liabilities (2012 - 2023)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Other Non-Current Liabilities came in at $8.3 million in Q4 2023, up 204.25% quarter-over-quarter from $2.7 million in Q1 2012.
Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Liabilities (2012 - 2023) Analysis & Trends
Tonix Pharmaceuticals Holding's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $8.3 million for Q4 2023.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $8.3 million in Q4 2023; TTM through Dec 2023 was $8.3 million, a N/A change from a year earlier, with the FY2023 full-year figure at $8.3 million, changed N/A from the prior year.
- Other Non-Current Liabilities improved to $8.3 million in Q4 2023 per TNXP's latest filing, from $2.7 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $8.3 million in Q4 2023 and bottomed at $8.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Tonix Pharmaceuticals Holding | 142.07 Mn | 142.07 Mn | 5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 8.26 Mn |
| Mar 31, 2012 | 2.71 Mn |